Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 14,000 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. The trade was a 14.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00.

Kiniksa Pharmaceuticals Stock Down 2.1 %

Kiniksa Pharmaceuticals stock opened at $19.28 on Thursday. The stock’s fifty day simple moving average is $19.88 and its 200-day simple moving average is $22.96. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Quarry LP purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at approximately $50,000. CWM LLC lifted its holdings in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares in the last quarter. nVerses Capital LLC acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $80,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at $158,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after buying an additional 1,004 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on KNSA. Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.